CinCor Pharma, Inc.
(NASDAQ : CINC)

( )
CINC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.48%166.090.7%$1108.87m
PFEPfizer Inc. -0.72%49.750.9%$939.86m
ABBVAbbVie, Inc. -0.22%142.291.9%$831.12m
MRKMerck & Co., Inc. -0.47%90.590.7%$806.25m
LLYEli Lilly & Co. 1.90%313.931.1%$798.53m
BMYBristol-Myers Squibb Co. -1.36%74.541.0%$648.45m
SIGASIGA Technologies, Inc. 5.66%26.150.0%$514.56m
AZNAstraZeneca Plc 0.26%66.811.0%$373.58m
GBTGlobal Blood Therapeutics, Inc. 0.43%67.045.6%$334.64m
ALNYAlnylam Pharmaceuticals, Inc. -1.21%231.018.2%$285.62m
GSKGSK Plc -3.08%34.920.3%$275.20m
HZNPHorizon Therapeutics Plc -3.81%64.905.4%$222.52m
KRTXKaruna Therapeutics, Inc. -1.34%273.710.0%$217.12m
CCXIChemoCentryx, Inc. 0.18%50.812.9%$205.42m
RGENRepligen Corp. 1.74%255.736.7%$190.66m

Company Profile

CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The firm is developing CIN-107 for the treatment of multiple diseases where aldosterone plays a significant role in disease pathophysiology, including hypertension and primary aldosteronism, as well as its utility in ameliorating complications of chronic kidney disease. The company was founded by Jon Isaacsohn and Catherine Pearce on March 28, 2018 and is headquartered in Waltham, MA.